The University of Southampton
University of Southampton Institutional Repository

Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study

Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study
Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study

OBJECTIVE: To evaluate the relationship between anti-tumour necrosis factor (TNF) use and surgical resection rates in a regional paediatric inflammatory bowel disease (IBD) cohort.

METHODS: This retrospective cohort study used prospectively maintained electronic data from a regional UK paediatric gastroenterology centre (2007-2024). Included were individuals with modified Porto IBD diagnosis, aged ≤17 years. Annual prevalent IBD population was estimated using incident diagnoses and transition to adult services. Abdominal surgery rates (strictureplasty, resection, primary stoma) and anti-TNF administration were collected and prevalence calculated. Three anti-TNF epochs, defined by the European Crohn's and Colitis Organisation/European Society of Paediatric Gastroenterology, Hepatology and Nutrition guidelines in 2014 and 2020, were compared: Epoch-1 (2007-2013; <20% anti-TNF), Epoch-2 (2014-2020; 20%-50%) and Epoch-3 (2021-2024; >50%). Kaplan-Meier analysis with log-rank testing compared surgery-free survival between early and later anti-TNF treatment groups.

RESULTS: One thousand five hundred and thirty-eight children were included (915 Crohn's disease (CD), 529 ulcerative colitis (UC) and 94 IBD-unclassified). Median age at diagnosis was 13.3 years, and the prevalent population increased (253-597 patients). Anti-TNF-treated prevalence rose across epochs (5.9%, 31.9%, 61.1%; p<0.001). Resection rates declined 3.93%, 1.57% and 1.09% (Epoch 1-3) (p=0.003). Rates did not significantly decrease from Epoch 2 to 3 (p=0.217). CD surgery significantly decreased (4.9%, 1.7%, 1.5%, p=0.006); trends in UC rates did not reach significance (1.89%, 1.55%, 0.56%, p=0.314). Time to anti-TNF from diagnosis decreased (1.2, 0.8 and 0.26 years, p=0.008). Early vs later anti-TNF initiation was not associated with surgery-free survival.

CONCLUSION: We report a significant increase in anti-TNF prevalence, with earlier deployment. Surgical resection rates have declined and plateaued; reflecting reduced CD surgery. Future research should focus on optimised anti-TNF and second-line biologic deployment to move beyond current levels of surgery.

2054-4774
Green, Zachary
b3269022-c0a6-42db-859d-d92c4cc5f4f0
Nicholas, Myrna
c5a1af5b-3b38-49b8-a46b-d323fae0df98
Vuijk, Stephanie
8a84ca7f-6643-4c6e-a1dc-1faebc7da0c4
Stanton, Mike
2eeae5fc-23c6-4d7d-80c6-f74efaf677f4
Bakewell, Christopher
0e949bd2-97a5-411a-8e5e-aee8320953ec
Coelho, Tracy
a78b627c-ea78-41e1-9553-0390921e3c93
Batra, Akshay
822f891e-87ca-41d9-b68d-27c395e88809
Afzal, Nadeem
5148f35e-6788-4dbd-a50f-c303a4948d60
Ennis, Sarah
7b57f188-9d91-4beb-b217-09856146f1e9
Beattie, Robert M
9a66af0b-f81c-485c-b01d-519403f0038a
Ashton, James
03369017-99b5-40ae-9a43-14c98516f37d
Green, Zachary
b3269022-c0a6-42db-859d-d92c4cc5f4f0
Nicholas, Myrna
c5a1af5b-3b38-49b8-a46b-d323fae0df98
Vuijk, Stephanie
8a84ca7f-6643-4c6e-a1dc-1faebc7da0c4
Stanton, Mike
2eeae5fc-23c6-4d7d-80c6-f74efaf677f4
Bakewell, Christopher
0e949bd2-97a5-411a-8e5e-aee8320953ec
Coelho, Tracy
a78b627c-ea78-41e1-9553-0390921e3c93
Batra, Akshay
822f891e-87ca-41d9-b68d-27c395e88809
Afzal, Nadeem
5148f35e-6788-4dbd-a50f-c303a4948d60
Ennis, Sarah
7b57f188-9d91-4beb-b217-09856146f1e9
Beattie, Robert M
9a66af0b-f81c-485c-b01d-519403f0038a
Ashton, James
03369017-99b5-40ae-9a43-14c98516f37d

Green, Zachary, Nicholas, Myrna, Vuijk, Stephanie, Stanton, Mike, Bakewell, Christopher, Coelho, Tracy, Batra, Akshay, Afzal, Nadeem, Ennis, Sarah, Beattie, Robert M and Ashton, James (2026) Escalating anti-tumour necrosis factor exposure with reductions in surgical resection rates in paediatric inflammatory bowel disease: an 18-year real-world population-based cohort study. BMJ Open Gastroenterology, 13 (1), [e002344]. (doi:10.1136/bmjgast-2026-002344).

Record type: Article

Abstract

OBJECTIVE: To evaluate the relationship between anti-tumour necrosis factor (TNF) use and surgical resection rates in a regional paediatric inflammatory bowel disease (IBD) cohort.

METHODS: This retrospective cohort study used prospectively maintained electronic data from a regional UK paediatric gastroenterology centre (2007-2024). Included were individuals with modified Porto IBD diagnosis, aged ≤17 years. Annual prevalent IBD population was estimated using incident diagnoses and transition to adult services. Abdominal surgery rates (strictureplasty, resection, primary stoma) and anti-TNF administration were collected and prevalence calculated. Three anti-TNF epochs, defined by the European Crohn's and Colitis Organisation/European Society of Paediatric Gastroenterology, Hepatology and Nutrition guidelines in 2014 and 2020, were compared: Epoch-1 (2007-2013; <20% anti-TNF), Epoch-2 (2014-2020; 20%-50%) and Epoch-3 (2021-2024; >50%). Kaplan-Meier analysis with log-rank testing compared surgery-free survival between early and later anti-TNF treatment groups.

RESULTS: One thousand five hundred and thirty-eight children were included (915 Crohn's disease (CD), 529 ulcerative colitis (UC) and 94 IBD-unclassified). Median age at diagnosis was 13.3 years, and the prevalent population increased (253-597 patients). Anti-TNF-treated prevalence rose across epochs (5.9%, 31.9%, 61.1%; p<0.001). Resection rates declined 3.93%, 1.57% and 1.09% (Epoch 1-3) (p=0.003). Rates did not significantly decrease from Epoch 2 to 3 (p=0.217). CD surgery significantly decreased (4.9%, 1.7%, 1.5%, p=0.006); trends in UC rates did not reach significance (1.89%, 1.55%, 0.56%, p=0.314). Time to anti-TNF from diagnosis decreased (1.2, 0.8 and 0.26 years, p=0.008). Early vs later anti-TNF initiation was not associated with surgery-free survival.

CONCLUSION: We report a significant increase in anti-TNF prevalence, with earlier deployment. Surgical resection rates have declined and plateaued; reflecting reduced CD surgery. Future research should focus on optimised anti-TNF and second-line biologic deployment to move beyond current levels of surgery.

This record has no associated files available for download.

More information

Accepted/In Press date: 15 May 2026
e-pub ahead of print date: 24 June 2026

Identifiers

Local EPrints ID: 512967
URI: https://eprints.soton.ac.uk/id/eprint/512967
ISSN: 2054-4774
PURE UUID: 395d99f4-f15c-45b3-8ca9-525f0bc91e12
ORCID for Zachary Green: ORCID iD orcid.org/0000-0002-2907-5538
ORCID for Sarah Ennis: ORCID iD orcid.org/0000-0003-2648-0869
ORCID for James Ashton: ORCID iD orcid.org/0000-0003-0348-8198

Catalogue record

Date deposited: 28 Jul 2026 16:51
Last modified: 13 Sep 2026 15:49

Export record

Altmetrics

Contributors

Author: Zachary Green ORCID iD
Author: Myrna Nicholas
Author: Stephanie Vuijk
Author: Mike Stanton
Author: Christopher Bakewell
Author: Tracy Coelho
Author: Akshay Batra
Author: Nadeem Afzal
Author: Sarah Ennis ORCID iD
Author: Robert M Beattie
Author: James Ashton ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×